Merus (NASDAQ:MRUS) Receives $29.40 Average Price Target from Brokerages

Shares of Merus (NASDAQ:MRUS) have received an average rating of “Buy” from the eight brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $29.40.

MRUS has been the topic of a number of analyst reports. William Blair reiterated a “buy” rating on shares of Merus in a research note on Friday, June 11th. Zacks Investment Research lowered Merus from a “hold” rating to a “sell” rating in a research note on Wednesday, August 11th. upgraded Merus from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $24.00 to $31.00 in a research note on Monday, June 7th. Citigroup upgraded Merus from a “neutral” rating to a “buy” rating in a research note on Monday, June 7th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Merus in a research note on Monday, August 9th.

In related news, SVP Lex Bakker sold 3,860 shares of the stock in a transaction dated Thursday, July 1st. The stock was sold at an average price of $21.05, for a total transaction of $81,253.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Kruif John De sold 2,787 shares of the stock in a transaction dated Thursday, August 12th. The shares were sold at an average price of $19.34, for a total value of $53,900.58. Following the sale, the senior vice president now owns 15,830 shares of the company’s stock, valued at $306,152.20. The disclosure for this sale can be found here. Insiders sold a total of 2,192,669 shares of company stock valued at $45,495,110 over the last quarter. Company insiders own 2.90% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRUS. Macquarie Group Ltd. bought a new position in shares of Merus in the 2nd quarter worth approximately $27,000. UBS Group AG raised its position in shares of Merus by 214.8% in the 1st quarter. UBS Group AG now owns 2,899 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 1,978 shares in the last quarter. Citigroup Inc. raised its position in shares of Merus by 3,238.6% in the 2nd quarter. Citigroup Inc. now owns 7,779 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 7,546 shares in the last quarter. Jump Financial LLC bought a new position in shares of Merus in the 2nd quarter worth approximately $202,000. Finally, Virtus ETF Advisers LLC bought a new position in shares of Merus in the 2nd quarter worth approximately $208,000. 69.61% of the stock is owned by institutional investors and hedge funds.

MRUS stock traded down $0.69 during midday trading on Wednesday, hitting $22.90. The company’s stock had a trading volume of 513,145 shares, compared to its average volume of 207,559. The stock’s 50-day moving average price is $21.83 and its 200 day moving average price is $21.82. Merus has a 1 year low of $11.19 and a 1 year high of $31.27. The stock has a market cap of $881.15 million, a price-to-earnings ratio of -8.42 and a beta of 0.59.

Merus (NASDAQ:MRUS) last issued its earnings results on Thursday, August 5th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.13). The firm had revenue of $12.38 million during the quarter, compared to the consensus estimate of $7.83 million. Merus had a negative net margin of 231.19% and a negative return on equity of 51.93%. Research analysts expect that Merus will post -2.34 earnings per share for the current year.

About Merus

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Further Reading: Trade Deficit

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.